Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931088 | 0.78 | CDA (0.64) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL11312120 | 0.77 | CDA (1.00) | CDAMAPTPYGMSLC28A1SLC28A2 | |
| SCHEMBL586993 | 0.77 | CDA (1.00) | CDAMAPTPYGMSLC28A1SLC28A2 | |
| SCHEMBL583301 | 0.77 | CDA (1.00) | CDAMAPTPYGMSLC28A1SLC28A2 | |
| SCHEMBL587033 | 0.77 | CDA (1.00) | CDAMAPTPYGMSLC28A1SLC28A2 | |
| SCHEMBL13030835 | 0.74 | CDA (0.65) | CDASLC29A1 | |
| SCHEMBL20211428 | 0.72 | CDA (0.52) | CDAMAPTPYGMSLC28A1SLC28A2 | |
| SCHEMBL28612080 | 0.72 | CDA (0.52) | CDAMAPTPYGMSLC28A1SLC28A2 | |
| SCHEMBL18512836 | 0.71 | CDA (0.66) | CDAMAPTPYGMSLC28A1SLC28A2 | |
| SCHEMBL399314 | 0.71 | CDA (0.66) | CDAMAPTPYGMSLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130116207-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8329666-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329665-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8324180-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | RNASE1, UNG, HCCS | CDA 537/4885MAPT 4204/4885PYGM 769/4885 |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | CDA 537/4885MAPT 4204/4885PYGM 769/4885 |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNG, DUT, DCTD | CDA 49/4885MAPT 4434/4885PYGM 2236/4885 |
| US-20130116207-A1 | Compositions and Methods for Treating Cancer | RNASE1, UNG, HCCS | CDA 537/4885MAPT 4204/4885PYGM 769/4885 |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | CDA 537/4885MAPT 4204/4885PYGM 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.